9.1 High standards must be maintained at all times.
9.2 All material and activities must recognise the special nature of medicines and the professional standing of the audience to which they are directed and must not be likely to cause offence.
9.3 The name or photograph of a member of a health profession must not be used in any way that is contrary to the conventions of that profession.
9.4 Promotional material must not imitate the devices, copy, slogans or general layout adopted by other companies in a way that is likely to mislead or confuse.
9.5 Promotional material must not include any reference to the Medicines Commission, the Commission on Human Medicines, the Committee on Safety of Medicines, the Medicines and Healthcare products Regulatory Agency, the Medicines Control Agency or the licensing authority, unless this is specifically required by the licensing authority.
9.6 Reproductions of official documents must not be used for promotional purposes unless permission has been given in writing by the appropriate body.
9.7 Extremes of format, size or cost of promotional material must be avoided.
9.8 Postcards, other exposed mailings, envelopes or wrappers must not carry matter which might be regarded as advertising to the public, contrary to Clause 22.1.
9.9 The telephone, text messages, email, telemessages, facsimile, automated calling systems and other electronic data communications must not be used for promotional purposes, except with the prior permission of the recipient.
9.10 Material relating to medicines and their uses, whether promotional or not, and information relating to human health or diseases which is sponsored by apharmaceutical company must clearly indicate that it has been sponsored by that company.
The only exception to this is market research material which need not reveal the name of the company involved but must state that it is sponsored by a pharmaceutical company.
The special nature of medicines and the professional audience to which the material is directed require that the standards set for the promotion of medicines are higher than those which might be acceptable for general commodity advertising.
It follows therefore that certain types, styles and methods of promotion, even where they might be acceptable for the promotion of products other than medicines, are unacceptable.
Where factual safety information given in promotional material is based on advice in the MHRA Drug Safety Update, the information can be referenced to that publication.
Back to clause Back to top
Particular care needs to be taken in this regard in the first six months following the launch of a medicine to avoid criticism of the industry.
Reply paid cards which are intended to be returned to companies through the post and which relate to a prescription only medicine should not bear both the name of the medicine and information as to its usage but may bear one or the other.
Where permission to use emails for promotional purposes has been given by a recipient, each email sent should inform the recipient as to how to unsubscribe to them.
An enquiry received by email can be responded to by email without specific permission, consent to do so being implied in such circumstances. There is no need to inform recipients as to how to unsubscribe to an email response to an enquiry.
The declaration of sponsorship must be sufficiently prominent to ensure that readers of sponsored material are aware of it at the outset.
The wording of the declaration must be unambiguous so that readers will immediately understand the extent of the company’s involvement and influence over the material. This is particularly important when companies are involved in the production of material which is circulated by an otherwise wholly independent party, such as supplements to health professional journals.
Where market research is carried out by an agency on behalf of a pharmaceutical company, the agency must reveal the name of its client to the Prescription Medicines Code of Practice Authority when the Authority requests it to do so. When commissioning market research, a company must take steps to ensure that its identity would be so made known to the Authority should a request for that information be made.